insurance companies that cover glp 1 drugs Why Won't Weight Loss Medications? The Real Story Behind Health Care Costs and Obesity Treatment Insurance stopped covering your GLP-1?
Description
Currently, there is an ongoing randomised double-masked placebo-controlled trial, the SUMMIT trial, studying the efficacy and safety of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and GLP-1 receptors, versus placebo in HFpEF patients with obesity (NCT04847557)
Abstract Objectives Glucagon-like peptide 1 (GLP-1) receptor agonists have recently proven to be an effective treatment for type 2 diabetes mellitus (T2DM)
A meta-analysis of clinical studies indicated that treatment with GLP-1RAs of obese patients with T2MD did not increase the risk of breast tumors, nor did it increase the risk of acute pancreatitis, pancreatic cancer, and overall tumor neoplasia (207209)

I am encouraged that theres a new avenue for therapy, and as these medications are developed and put into practice, says Peters, I think well be able to successfully identify who should be using them, who will be a good responder to the intervention, and who might need continued treatment. According to Malhotra, the bottom line is this: Diet, exercise, and sleep are the three pillars of health

doi:10.2337/diabetes.52.6.1449 163

Pure GIP agonists, when tested without GLP-1 agonism, havent shown impressive weight loss results in early studies
